Could a simpler eczema routine boost treatment success?

NCT ID NCT07661979

Not yet recruiting Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study explores whether giving people with mild-to-moderate eczema a straightforward treatment plan using only Opzelura cream helps them stick to their medication routine. Participants apply the cream twice daily until their skin clears, then as needed. Some participants also receive an Eczema Action Plan with lifestyle tips. The main goal is to see if this simple approach improves how often people use their medication over 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib (Opzelura cream)
What this could lead to: If successful, this could show that a simpler treatment plan helps people with eczema stick to their medication and improve their quality of life.
What could go wrong: This is a small, early-phase study focused on adherence, not on curing the disease. Results may not apply to all patients with eczema.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.